Tanshinone II A down-regulates HMGB1, RAGE, TLR4, NF-κB expression, ameliorates BBB permeability and endothelial cell function, and protects rat brains against focal ischemia

Brain Research

Volumn 1321, Issue , 2010, Pages 143-151

  Wang, Lina ^a   Zhang, Xiangjian ^a   Liu, Lingling ^a   Cui, Lili ^a   Yang, Rui ^a   Li, Min ^a   Du, Wei ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cerebral ischemia; High mobility group box 1; Neuroprotection; Nuclear factor B; Tanshinone II A

Indexed keywords

CLAUDIN 5; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; TANSHINONE IIA; TOLL LIKE RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN WATER; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; ENDOTHELIUM CELL; LOW DRUG DOSE; MALE; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; UPREGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN ISCHEMIA; CAPILLARY PERMEABILITY; DOWN-REGULATION; ENDOTHELIAL CELLS; GENE EXPRESSION; HMGB1 PROTEIN; MALE; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; NEUROPROTECTIVE AGENTS; NF-KAPPA B; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TOLL-LIKE RECEPTOR 4;

RATTUS;

EID: 77449130589     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.12.046     Document Type: Article

References (23)

1. Bederson J.B., Pitts L.H., Germano S.M., Nishimura M.C., Davis R.L., and Bartkowski H.M. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 17 (2008) 1304-1308
2. Chan P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J. Cereb. Blood Flow Metab. 21 1 (2001) 2-14
3. Cheatwood J.L., Emerick A.J., Schwab M.E., and Kartje G.L. Nogo-A expression after focal ischemic stroke in the adult rat. Stroke 39 7 (2008) 2091-2098
4. Clemens J.A., Stephenson D.T., Dixon E.P., Smalstig E.B., Mincy R.E., Rash K.S., and Little S.P. Global cerebral ischemia activates nuclear factor-kappa B prior to evidence of DNA fragmentation. Brain Res. Mol. Brain Res. 48 (1997) 187-196
5. Clemens J.A., Stephenson D.T., Yin T., Smalstig E.B., Panetta J.A., and Little S.P. Drug-induced neuroprotection from global ischemia is associated with prevention of persistent but not transient activation of nuclear factor-kappa B in rats. Stroke 29 (1998) 677-682
6. Du G., and Zhang J. The general situation and progress of the modern research of red sage root (Radix Salvia miltiorrhiza). Zhong Yao Cai 28 (2004) 301-304
7. Hatashita S., Hoff J.T., and Salamat S.M. Ischemic brain edema and the osmotic gradient between blood and brain. J. Cereb. Blood. Flow Metab. 8 (1988) 552-559
8. Huttunen H.J., and Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern Med. 255 (2004) 351-366
9. Ikeda K., Negishi H., and Yamori Y. Antioxidant nutrients and hypoxia/ischemia brain injury in rodents. Toxicology 189 (2003) 55-61
10. Jang S.I., Jeong S.I., Kim K.J., Kim H.J., Yu H.H., Park R., Kim H.M., and You Y.O. Tanshinone IIA from Salvia miltiorrhiza inhibits inducible nitric oxide synthase expression and production of TNF-alpha, IL-1beta and IL-6 in activated RAW 264.7cells. Planta Med. 69 (2003) 1057-1059
11. Kazuhide H., Kenichi M., Masanori N., Mai H., Shohei M., Masyuki F., Kensuke O., Nobuaki E., Katsunori I., and Michihihiro F. Delayed treatment with minocycline ameliorates neurologic impairment through activated microglia expressing a high-mobility group box1-inhibiting mechanism. Stroke 39 (2008) 951-958
12. Liu Y., Zhang X.J., Yang C.H., and Fan H.G. Oxymatrine protects rat brains against permanent focal ischemia and down-regulates NF-kappaB expression. Brain Res. 1268 (2009) 174-180
13. Longa E.Z., Weinstein P.R., Carlson S., and Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 20 (1989) 84-91
14. Lotze M.T., and Tracey K.J. High-mobility group box 1protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5 (2005) 331-342
15. Park J.S., Arcaroli J., Yum H.K., Yang H., Wang H., Yang K.Y., Choe K.H., Strassheim D., Pitts T.M., Tracey K.J., and Abraham E. Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol. Cell Physiol. 284 (2003) C870-C879
16. Park J.S., Gamboni-Robertson F., He Q., Svetkauskaite D., Kim J.Y., Strassheim D., Sohn J.W., Yamada S., Maruyama I., Banerjee A., Ishizaka A., and Abraham E. High-mobility group box 1 protein interacts with multiple toll-like receptors. Am. J. Physiol. Cell Physiol. 290 (2006) C917-C924
17. Scaffidi P., Misteli T., and Bianchi M.E. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418 (2002) 191-195
18. Simonyi A., Wang Q., Miller R.L., Yusof M., Shelat P.B., Sun A.Y., and Sun G.Y. Polyphenols in cerebral ischemia: novel targets for neuroprotection. Mol. Neurobiol. 31 (2005) 135-147
19. Stros M., Ozaki T., Bacikova A., Kageyama H., and Nakagawara A. HMGB1 and HMGB2 cell-specifically down-regulate the p53-and p73-dependent sequence-specific transactivation from the human Bax gene promoter. J. Biol. Chem. 277 (2002) 7157-7164
20. Tatlisumak T., Carano R.A., Takano K., Opgenorth T.J., Sotak C.H., and Fisher M. A novel endothelin antagonist, A-127722, attenuates ischemic lesion size in rats with temporary middle cerebral artery occlusion: a diffusion and perfusion MRI study. Stroke 29 4 (1998) 850-857
21. Yang C., Zhang X., Fan H., and Liu Y. Curcumin up-regulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia. Brain Res. 1282 (2009) 133-141
22. Yang H., Wang H., Czura C.J., and Tracey K.J. The cytokine activity of HMGB1. J. Leukoc. Biol. 78 (2005) 1-8
23. Zhou L., Zuo Z., and Chow M.S.S. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J. Clin. Pharmacol. 45 (2005) 1345-1359